--- title: "Armata Advances AP-SA02 Toward Phase 3 Trial Launch" type: "News" locale: "en" url: "https://longbridge.com/en/news/293209036.md" description: "Armata Pharmaceuticals (ARMP) advanced its AP-SA02 candidate toward a Phase 3 trial launch, submitting the protocol and responding to FDA feedback. The company completed engineering runs for clinical material and secured $2.5M in DoD funding. While analysts rate the stock a Buy with a $15 target, TipRanks' AI suggests Neutral due to weak financials and technical downtrends." datetime: "2026-07-20T11:28:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293209036.md) - [en](https://longbridge.com/en/news/293209036.md) - [zh-HK](https://longbridge.com/zh-HK/news/293209036.md) generator: "portal-rs" --- # Armata Advances AP-SA02 Toward Phase 3 Trial Launch An update from Armata Pharmaceuticals ( (ARMP) ) is now available. On July 20, 2026, Armata Pharmaceuticals reported notable progress across clinical, regulatory and manufacturing activities for AP-SA02, its intravenously administered multi-phage candidate for complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA. The company has submitted a complete Phase 3 superiority trial protocol and comprehensive responses to all FDA feedback from its End-of-Phase 2 meeting, reinforcing plans to start the pivotal study in the second half of 2026. Armata also completed four engineering runs of AP-SA02 at its Los Angeles cGMP facility, with production of Phase 3 clinical trial material as the next manufacturing step, and highlighted that AP-SA02 has QIDP and Fast Track designations following positive Phase 1b/2a data presented in October 2025. Financially, a further $2.5 million continuation award from the U.S. Department of Defense, bringing total DoD funding under this program to $28.7 million, supports Phase 3 readiness as the company explores additional funding options, while the promotion of David House to Chief Financial Officer strengthens its leadership bench for late-stage development and potential registration efforts. The most recent analyst rating on (ARMP) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page. **Spark’s Take on ARMP Stock** According to Spark, TipRanks’ AI Analyst, ARMP is a Neutral. ARMP scores low primarily due to very weak financial performance (large ongoing losses, negative equity, and persistent cash burn that increases financing/dilution risk). Technicals add pressure with a clear downtrend despite oversold readings. Corporate developments provide some offset (Fast Track, pediatric plan agreement, and DoD funding), but not enough to outweigh the current financial and trend risks; valuation offers limited support given negative earnings and no dividend. To see Spark’s full report on ARMP stock, click here. **More about Armata Pharmaceuticals** Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company specializing in high-purity, pathogen-specific bacteriophage therapeutics targeting antibiotic-resistant and difficult-to-treat bacterial infections. The company is advancing a pipeline of natural and synthetic phage candidates, including clinical programs for Pseudomonas aeruginosa and Staphylococcus aureus, supported by in-house phage-specific cGMP manufacturing capabilities aimed at eventual full commercial-scale production. Armata’s proprietary bacteriophage-based technology is designed to complement or enhance existing antibiotic regimens, with a focus on serious infectious disease indications such as complicated S. aureus bacteremia. By combining drug development expertise from bench to clinic with targeted phage cocktails like AP-SA02, the company seeks to strengthen its position in the emerging phage therapy segment of the anti-infective market, where resistance to conventional antibiotics is an expanding clinical and economic challenge. **Average Trading Volume:** 132,945 **Technical Sentiment Signal:** Sell **Current Market Cap:** $165.6M ### Related Stocks - [ARMP.US](https://longbridge.com/en/quote/ARMP.US.md) ## Related News & Research - [Armata says inhaled phage candidate AP-PA02 completes Phase 2 trials in cystic fibrosis, bronchiectasis patients](https://longbridge.com/en/news/297902417.md) - [Analyst Maintains Buy on Armata as AP-SA02 Nears Phase 3, Backed by Regulatory Tailwinds and $20 DCF-Based Price Target](https://longbridge.com/en/news/297360426.md) - [Arm CEO says AI could cure cancer. Data centers are creating a bottleneck.](https://longbridge.com/en/news/298273784.md) - [AI Could Eventually Crack Cancer and Drug Discovery, Says Arm CEO — But This Is What’s Holding It Back](https://longbridge.com/en/news/298315170.md) - [Arm expands Total Design program to physical AI with 80-plus ecosystem partners](https://longbridge.com/en/news/298248556.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**